Literature DB >> 2942155

Dialysis membranes and coagulation system.

M Notohamiprodjo, K Andrassy, J Bommer, E Ritz.   

Abstract

Artificial membranes used for hemodialysis differ from endogenous membranes, i.e. endothelial cells, by their variable thrombogenicity. The key step in activation of the coagulation system by dialysis membranes is thrombocyte activation which is preceded by formation of a protein layer of critical thickness. Crucial questions concerning the quality of this protein membrane as a determinant of thrombocyte activation are not well understood. Activation of the contact phase of the intrinsic plasmatic coagulation system by dialysis membranes is well documented. Local action of thrombin in the membrane microenvironment is documented by release of fibrinopeptide A and deposition of fibrin on the membrane. Apart from thrombin, other mechanisms, e.g. PMN elastase, plasma-independent activation of blood cells, facilitatory action of erythrocytes etc., may play a contributory role. With respect to the polycarbonate membrane, some authors find less platelet extraction and unchanged platelet release reaction. In our own studies, polycarbonate membranes were not superior to cuprophane membranes with respect to thrombogenicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942155     DOI: 10.1159/000169436

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

1.  Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting.

Authors:  C Le Feuvre; G Dambrin; G Helft; F Beygui; M Touam; J P Grünfeld; A Vacheron; J P Metzger
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

2.  Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.

Authors:  Shunji Shiohira; Takumi Yoshida; Hidekazu Sugiura; Satsuki Yoshida; Michihiro Mitobe; Katsunori Shimada; Takashi Ohba; Ken Tsuchiya; Takashi Kabaya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-07-20       Impact factor: 2.801

3.  Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.

Authors:  Hideki Ishii; Yoshitake Kumada; Takanobu Toriyama; Toru Aoyama; Hiroshi Takahashi; Shigeki Yamada; Yoshinari Yasuda; Yukio Yuzawa; Shoichi Maruyama; Seiichi Matsuo; Tatsuaki Matsubara; Toyoaki Murohara
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

4.  Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.

Authors:  Yukihisa Ogawa; Hiroyoshi Yokoi; Takao Ohki; Kimihiko Kichikawa; Masato Nakamura; Kimihiro Komori; Shinsuke Nanto; Erin E O'Leary; Aaron E Lottes; Alan T Saunders; Michael D Dake
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-09       Impact factor: 2.740

5.  Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.

Authors:  Andreas Link; Matthias Girndt; Simina Selejan; Ranja Rbah; Michael Böhm
Journal:  Crit Care       Date:  2008-08-29       Impact factor: 9.097

6.  Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study.

Authors:  Hsin-Fu Lee; Lung-Sheng Wu; Yi-Hsin Chan; Cheng-Hung Lee; Jia-Rou Liu; Hui-Tzu Tu; Ming-Shien Wen; Chi-Tai Kuo; Wei-Jan Chen; Yung-Hsin Yeh; Lai-Chu See; Shang-Hung Chang
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.